surmount-osa trial tirzepatide results for the Treatment of Obstructive Sleep Apnea and Obesity 🔗 @NEJM 🔗 https://t.co/RKdvTJxd7Y #ADA2024 Tirzepatide shows dual benefits in

Last accessed: May 2025

The BDA advises adults not to exceed 600 micrograms a day

From baseline, the mean percentage change in body weight was 11.5, 13.9, and 15.3 percent with 4, 9, and 12 mg of retatrutide, respectively, versus 2.6 percent with placebo

NICE recommend tirzepatide and semaglutide for patients with at least one weight-related comorbidity and a BMI 35 kg/m 2 (or BMI 30 kg/m 2 and who meet the criteria for referral to specialist weight management services, for semaglutide only) and liraglutide for patients with a BMI 35 kg/m 2 , non-diabetic hyperglycaemia, and a high risk of cardiovascular disease

In a large Phase 3 clinical trial published in the New England Journal of Medicine, people who took the highest dose of the Wegovy pill lost an average of 16.6 percent of their body weight after 64 weeks

Additionally, we intend to examine current social media trends associated with semaglutide